Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
Orion Corporation: Decisions by the AGM on 25 March 200825 Mar 2008
Orion Corporation: Transfer of own shares20 Mar 2008
ORION CORPORATION ACQUISITION OF OWN SHARES 20.3.200820 Mar 2008
ACQUISITION OF OWN SHARES 19.3.200819 Mar 2008
ACQUISITION OF OWN SHARES 18.3.200819 Mar 2008
ORION CORPORATION ACQUISITION OF OWN SHARES 17.3.200818 Mar 2008
Orion Group Annual Report 2007 published28 Feb 2008
ORION OYJ: GTx ANNOUNCED PHASE III CLINICAL DATA FOR TOREMIFENE CITRATE 80 mg
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
25 Feb 2008
Orion Group Financial Review of 20077 Feb 2008
Matters to be handled at Orion's AGM on 25 March 20087 Feb 2008
Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo®7 Feb 2008
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 20077 Feb 2008
  • Previous
  • 1
  • More pages
  • 75
  • 76
  • 77
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130